45results about How to "Improve pathological damage" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum TY-P23 and application thereof, and the preservation number of the lactobacillus plantarum TY-P23 is CGMCC No: 30876. The lactobacillus plantarum TY-P23 has the functions of remarkably improving the immunity of the body and improving the intestinal injury of the body.

The invention discloses a Lactobacillus paracasei metagen with a constipation relieving effect and application thereof, and belongs to the field of microorganisms. The lactobacillus paracasei CCFM1452 provided by the invention is relatively good in activity, and has certain acid and alkali resistance and adhesion. According to the present invention, with the application of the lactobacillus paracasei CCFM1452, the inflammation level in the colon tissue can be significantly reduced, the pathological damage of the colon tissue can be improved, the levels of the proinflammatory factor and the anti-inflammatory factor can be adjusted, the aquaporin expression level can be reduced, and the motilin MTL content in the colon tissue can be increased; the content of vasoactive intestinal peptide VIP in the colon tissue is reduced; the compound has the advantages of enhancing intestinal tract movement, shortening intestinal tract transfer time and regulating intestinal tract steady state, and has a huge application prospect in preparation of medicines for relieving constipation.

The invention belongs to the technical field of biological medicines, and particularly relates to schisandra chinensis exosome-like vesicles and application thereof in preparation of anti-depression products. The schisandra chinensis exosome-like nano-vesicles are prepared by a method of combining differential centrifugation with ultra-high-speed centrifugation. The prepared exosome-like nano vesicles derived from schisandra chinensis can be taken in by nerve microglial cells, and the inflammatory response induced by LPS is inhibited; meanwhile, the LPS-induced mouse depression-like behavior can be improved, and the pathological injury of the hippocampus can be relieved. The invention establishes the preparation method of the schisandra chinensis exosome-like nano-vesicle, and verifies that the schisandra chinensis exosome-like nano-vesicle has an anti-depression effect, so that the schisandra chinensis exosome-like nano-vesicle has a relatively good development and utilization prospect.

The invention provides an application of a compound as shown in a formula I, cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury, and application of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury. The compound shown in the formula I can obviously reduce proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) of an acute lung injury rat model, improve infiltration of inflammatory cells (including mononuclear / macrophage, lymphocyte and neutrophil) in lung tissues, improve pathological injury of the lung tissues, improve lung functions, and improve the curative effect of the lung. The above results show that the compound represented by the formula I can be used for prevention, alleviation, adjuvant therapy or treatment of lung injury, especially acute lung injury or a combined disease thereof or acute respiratory distress syndrome or a combined disease thereof.

The invention relates to the technical field of medicines, in particular to a traditional Chinese medicine composition for treating acne and a preparation method thereof. The traditional Chinese medicine composition comprises the following components in parts by weight: 270 parts of humifuse euphorbia herb, 90 parts of chinaroot greenbrier, 63 parts of aloe, 45 parts of fructus chebulae, 45 parts of fructus chebulae immaturus, 45 parts of tamarind, 45 parts of ziziphus jujube, 45 parts of polypody yunnanensis and 25 parts of scammonia resina. The traditional Chinese medicine composition provided by the invention has a remarkable inhibition effect on acne inflammatory response induced by propionibacterium acnes.

The invention discloses a method for treating leucopenia by analyzing active ingredients of a Qigui Shengbai capsule based on network pharmacology and application of the method. According to the method, main effective components of the Qiguo Liangbai capsule are identified firstly, potential targets and mechanisms of the Qiguo Liangbai capsule are further predicted, and a component-target-signal channel network diagram of the Qiguo Liangbai capsule is constructed by combining network pharmacological analysis of transcriptome and metabonomics; and molecular biology is utilized to verify the component-target-signal path network diagram, and a theoretical basis is further provided for clinical application of the Qigui Liangbai capsule to treatment of leucopenia.

The invention belongs to the technical field of biological medicine, and particularly relates to application of CNPY2 as a new target in diagnosis and treatment of diabetic nephropathy. The invention provides a biomarker CNPY2 gene or CNPY2 protein for auxiliary diagnosis of diabetic nephropathy for the first time. The expression of the CNPY2 in the renal tubule of a DN patient is up-regulated, the expression of the CNPY2 in the renal tubule of a db / db mouse is up-regulated, and the expression of the CNPY2 in an HK-2 cell subjected to in-vitro high-glucose culture is up-regulated; therefore, the CNPY2 can be used as an auxiliary diagnosis index of the diabetic nephropathy for auxiliary diagnosis of the diabetic nephropathy. The invention also provides a kit for auxiliary diagnosis of diabetic nephropathy. The kit contains a detection reagent of the CNPY2 gene or the coded protein. The invention also finds that by knocking down the adeno-associated virus through the CNPY2 and inhibiting the expression or activity of the CNPY2 through the specific small interfering RNA of the adeno-associated virus, the pathological injury of the renal tubules of db / db mice can be obviously improved, the integrity of MAM in the renal tubule epithelial cells is improved, and the ferroptosis, ERS and mitochondrial injury of the renal tubule epithelial cells are alleviated; therefore, the CNPY2 can be used as a drug, a drug target or a target gene in gene therapy, and is applied to prevention, alleviation or / and treatment of diabetic nephropathy.

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus mucus fermentation TY-M26 and application of the lactobacillus mucus fermentation TY-M26, and the preservation number of the lactobacillus mucus fermentation TY-M26 is CGMCC (China General Microbiological Culture Collection Center) No. 32238. The lactobacillus mucilaginosus TY-M26 has high inhibitory activity on alpha-glucosidase activity, and animal experiments prove that the lactobacillus mucilaginosus TY-M26 can significantly relieve diabetes characteristics of mice with type II diabetes, significantly reduce fasting blood-glucose level, significantly improve insulin resistance and serum insulin level, significantly reduce serum Glu level and serum TG level, and can be used for preparing medicines for treating diabetes mellitus. The pathological injury of pancreatic tissues is obviously improved; the lactobacillus mucilaginosus TY-M26 has the advantages that the lactobacillus mucilaginosus TY-M26 can be used for preparing the lactobacillus mucilaginosus TY-M26, the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues can be obviously improved, a certain protection effect on the liver is achieved, and the lactobacillus

The invention belongs to the field of biological medicine, and particularly relates to application of forsythiaside A in preparation of a medicine for relieving or treating diabetic cardiomyopathy. The forsythiaside A relieves or treats diabetic cardiomyopathy by regulating NLRP3 activation induced by endoplasmic reticulum stress. The forsythiaside A can reduce the levels of BG, GSP, TG, LDH, CK-MB, cTnI, MDA, IL-1beta, IL-6 and TNF-alpha of STZ induced diabetic mice, and meanwhile, the levels of IN and SOD are increased. The forsythiaside A can be used for reducing the expression levels of IL-1beta, IL-6, TNF-alpha, GRP78, TXNIP and NLRP3 in H9c2 cells induced by Glu. Therefore, forsythiaside A can induce NLRP3 inflammasome activation through endoplasmic reticulum stress to relieve diabetic cardiomyopathy, and a theoretical basis is provided for treating diabetic cardiomyopathy.

The application discloses a goose plasma protein-derived oligopeptide capable of improving liver lipid metabolism disorder and application thereof, and relates to the field of biotechnology.The goose plasma protein-derived oligopeptide capable of improving liver lipid metabolism disorder is screened by the application, and the amino acid sequence is GDWIVK.Animal experiment verification shows that the goose plasma protein-derived oligopeptide can effectively reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and liver affected by high-fat diet, increase the content of high-density lipoprotein cholesterol, reduce liver lipid deposition and improve liver pathological damage.Meanwhile, the goose plasma protein-derived oligopeptide can regulate the structure and diversity of intestinal flora, increase the abundance of beneficial bacteria and the content of short-chain fatty acids in feces, reduce the inflammatory response of colon, and play a synergistic regulation role through the intestinal-liver axis.

The invention discloses procyanidine B2G2 from purple sweet potato Ningzi No.4 and application thereof, and belongs to the technical field of biological medicine, the molecular formula of the procyanidine B2G2 is C44H34O20, and the molecular weight of the procyanidine B2G2 is 882.736 Da. The procyanidine B2G2 remarkably relieves acute lung injury ALI by inhibiting inflammatory response and ferroptosis induced by klebsiella pneumoniae KP; experiments show that B2G2 can reduce the lung tissue injury score, the lung wet / dry ratio, the expression of inflammatory factors TNF-alpha, IL-6 and IL-1beta and the bacterial load, and up-regulate the expression of ferroptosis related proteins GPX4, SLC7A11 and HO-1; in addition, B2G2 is non-toxic to liver and kidney functions and has good safety, and the application provides a new drug candidate scheme for preparation of drugs for treating acute lung injury.

The application provides a low-deuterium water red ginseng and rhodiola compound mask as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. The low-deuterium water red ginseng and rhodiola compound mask provided by the application comprises the following raw materials: a red ginseng and rhodiola compound, low-deuterium water, hydroxyethyl cellulose, carbomer-980, carbomer-981, panthenol, 1,2-hexanediol, p-hydroxyphenylacetone, glycerol, dipropylene glycol, beta-glucan, sodium alginate, disodium EDTA, betaine, allantoin, 1,3-butanediol, PEG-40 hydrogenated castor oil and tromethamine; the red ginseng and rhodiola compound is composed of red ginseng extract and rhodiola extract. The low-deuterium water red ginseng and rhodiola compound mask provided by the application has the effects of antioxidation, whitening and anti-photoaging, and can realize synergistic whitening and anti-photoaging.

The present invention provides an adhesion-enhanced engineered probiotic and its application, wherein the bacterium contains a recombinant plasmid pBbB8K‑LFCA‑FaeG‑FaeC. The engineered probiotic has a strong adhesion to intestinal epithelial cells, and competitively inhibits the adhesion of pathogenic Escherichia coli K88 to intestinal epithelial cells. The engineered probiotic of the present invention is a non-antibiotic Escherichia coli, which is more environmentally friendly and avoids antibiotic tolerance for animals. Immunizing animals with it has a better immune effect, can activate dendritic cells in Peyer's patches and mesenteric lymph nodes, promote T cell and B cell immune responses, maintain the integrity of the intestinal barrier to resist pathogen infection and improve intestinal inflammation, improve the abundance of intestinal probiotics, and reduce the abundance of pathogenic bacteria. The adhesion-enhanced probiotic prepared by the present invention can significantly inhibit bacterial enteritis in mice, providing an effective treatment for inflammatory bowel disease and other gastrointestinal diseases.

The invention belongs to the technical field of bacterial strain application, and particularly relates to application of bifidobacterium lactis TY-S01 or a product thereof in preparation of a preparation for preventing or improving or treating diabetes. Animal experiments prove that the bifidobacterium lactis TY-S01 can obviously relieve diabetes characteristics (weight loss and water intake increase) of type II diabetic mice, obviously reduce fasting blood-glucose level, obviously improve insulin resistance and serum insulin level, obviously reduce serum glycosylated hemoglobin A1c level, serum Glu level and serum TG level, and can obviously inhibit the diabetes mellitus of the type II diabetic mice, so that the bifidobacterium lactis TY-S01 can be used for treating diabetes mellitus of the type II diabetic mice. The pathological injury of pancreatic tissues is obviously improved; the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues is obviously improved, and a certain protection effect is achieved on the liver.

The invention belongs to the technical field of plant polysaccharides, and particularly relates to Chinese wolfberry fruit polysaccharides with the effects of resisting oxidation, enhancing immunity and promoting growth and application of the Chinese wolfberry fruit polysaccharides in healthy breeding of poultry. Tests prove that the fructus lycii polysaccharide is prepared by taking fructus lycii as a raw material and adopting water extraction and alcohol precipitation, and in-vivo and in-vitro experiments prove that the fructus lycii polysaccharide simultaneously has the effects of resisting oxidation, enhancing immunity and promoting growth and has good health-care and treatment values. Meanwhile, the extraction method of the wolfberry fruit polysaccharide in the technical scheme is simple and low in cost, has universality, is easy for large-scale production, and has a good development prospect.

The invention belongs to the technical field of biological medicines, and particularly discloses a liposome containing a natural extract composition as well as a preparation method and application of the liposome. The method for preparing the liposome containing the natural extract composition comprises the following steps: S1, adding the grape, poria cocos and apple extract, cholesterol and lecithin into an organic solvent, heating, stirring and dissolving to obtain an organic phase; adding the soybean extract and the ginseng extract into ultrapure water, heating and stirring to obtain a water phase; and S2, slowly adding the organic phase into the water phase while stirring, continuing stirring and emulsifying, and removing the organic solvent by reduced pressure distillation to obtain a liposome suspension. And S3, filtering the suspension, adding a freeze-drying protective additive, and freeze-drying to obtain the liposome. The invention also covers the application of the liposome in treating renal failure. In the invention, through the combination of natural extracts and the combination of a specific composition and liposome administration, the components generate a synergistic effect, and the pharmaceutical composition has a remarkable treatment effect on renal failure, especially chronic renal failure.

The present application relates to the application of cereal bran oligopeptide in the preparation of drugs and / or products for preventing and / or treating colorectal cancer metastasis, and belongs to the technical field of medical uses. The amino acid sequence of the cereal bran oligopeptide is shown in SEQ ID NO. 1 or SEQ ID NO. 2. The cereal bran oligopeptide can target and antagonize the activation of integrin alpha v beta 6 and alpha v beta 3 subtypes, effectively block the metastasis of colorectal cancer to distant organs such as liver and lung, significantly weaken the adhesion and invasion ability of colorectal adenocarcinoma cells, reduce the number of organ metastatic nodules, reduce the weight of organs, significantly improve the pathological damage of organ tissues, and has the advantages of high safety, small side effects, good biocompatibility, easy absorption and the like.

This invention discloses the application of Polygonatum oligosaccharides in the preparation of products that improve sperm motility. The molecular weight of the Polygonatum oligosaccharides is 1 × 10⁻⁶. 4 ~5×10 4 This oligosaccharide, Da, can be prepared through steps including ethanol defatting, water extraction, 30%-50% ethanol precipitation, and protein removal. Experiments show that this oligosaccharide can significantly improve sperm motility, particularly restoring the forward sperm motility rate in asthenospermia model mice to over 32%, reaching the clinical treatment threshold; it can also effectively alleviate cyclophosphamide-induced reproductive damage and improve testicular tissue pathological damage. Furthermore, this oligosaccharide can upregulate the expression of sperm motility-related genes such as Crisp2 and Catsper, downregulate miR-27 expression, and has multiple effects including reducing oxidative stress, inhibiting inflammation, and improving reproductive hormone levels. Therefore, this oligosaccharide can be used to prepare products that improve sperm motility, prevent and / or treat asthenospermia, and alleviate chemotherapy-related reproductive damage.

The present invention discloses an application of eleutheroside E or its pharmaceutical salt in the preparation of a drug for preventing or treating severe acute pancreatitis. Studies have found that eleutheroside E has a significant effect on resisting severe acute pancreatitis. The present invention has been proved by animal experiments: 3.5% sodium taurocholate was used to retrograde pancreaticobiliary injection to induce severe acute pancreatitis mouse model experiments, and it was found that eleutheroside E can significantly reduce the activity levels of serum amylase and lipase in mice, significantly reduce the iron content of pancreatic tissue in mice, reduce the oxidative stress response index MDA, ROS level, increase GSH level, increase Nrf2, HO-1, GPX4 protein expression levels, reduce the iron death marker ACSL4 protein expression level, and improve pancreatic tissue pathological damage. Therefore, eleutheroside E can prevent or treat severe acute pancreatitis.

The present invention provides microglia-derived exosomes and a preparation method and application thereof. The present invention provides a preparation method of microglia-derived exosomes, the preparation method comprising: culturing microglia in a culture medium containing gardenia glycosides, ligustrazine and puerarin to secrete exosomes, thereby obtaining microglia-derived exosomes. The microglia-derived exosomes prepared by the present invention can reduce neuroinflammation, inhibit oxidative stress and ferroptosis, reduce cerebral infarction volume, improve ischemia-reperfusion neurological scores, and improve brain tissue pathological damage, and have a neuroprotective effect on cerebral ischemia-reperfusion injury.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum TY-M21 and application of the lactobacillus plantarum TY-M21, and the preservation number of the lactobacillus plantarum TY-M21 is CGMCC (China General Microbiological Culture Collection Center) No. 29230. The lactobacillus plantarum TY-M21 has relatively high inhibitory activity on alpha-glucosidase activity, and animal experiments prove that the lactobacillus plantarum TY-M21 can be used for remarkably relieving diabetes characteristics of mice with type II diabetes, remarkably reducing fasting blood-glucose level, remarkably improving insulin resistance and serum insulin level, remarkably reducing serum Glu level and serum TG level, and remarkably improving insulin resistance and serum insulin level. The pathological injury of pancreatic tissues is obviously improved; the lactobacillus plantarum TY-M21 has the advantages that the lactobacillus plantarum TY-M21 can be used for preparing the lactobacillus plantarum TY-M21, the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues can be obviously improved, a certain protection effect on the liver is achieved, and the lactobacillus plantarum TY-M21 has

The invention discloses goose plasma protein source oligopeptide capable of improving liver lipid metabolism disorder and application of the goose plasma protein source oligopeptide, and relates to the technical field of biology. The goose plasma protein source oligopeptide capable of improving liver lipid metabolism disorder is obtained through screening, and the amino acid sequence is GDWIVK. Animal experiments prove that the goose plasma protein source oligopeptide can effectively reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and liver affected by high fat diet, increase the content of high-density lipoprotein cholesterol, reduce liver lipid deposition and improve pathological injury of the liver. Meanwhile, the structure and diversity of intestinal flora can be adjusted, the abundance of beneficial bacteria and the content of short-chain fatty acid in excrement are increased, the reaction of colitis is relieved, and the synergistic adjustment effect is achieved through an intestinal tract-liver axis.

The invention discloses application of piperlongumine in treating and preventing lung injury, and belongs to the technical field of medicines. Aiming at the technical bottlenecks of limited treatment means and high case fatality rate of the existing acute lung injury (ALI) / acute respiratory distress syndrome (ARDS), the invention discovers that piperlongumine can specifically inhibit cGAS-STING signal channel activation for the first time, and expression release of inflammatory factors IFN-beta, IL-6 and TNF-alpha is reduced by regulating phosphorylation of a downstream interferon regulatory factor 3 (IRF3). In-vitro experiments prove that piperlongumine inhibits ISD-induced inflammatory response in a dose-dependent manner, and in-vivo experiments show that piperlongumine can significantly relieve LPS-induced mouse acute lung tissue inflammatory cell infiltration, reduce serum IL-6 and TNF-alpha levels, and improve lung tissue pathological injury. According to the invention, the medicinal application of piperlongumine is expanded, a new lung injury treatment scheme based on natural active compounds is provided, and the piperlongumine can be widely applied to prevention and treatment of acute lung injury and related inflammatory lung diseases.

The invention provides application of herbacetin in preparation of a medicine for treating pneumonia injury. Experimental results show that after the herbacetin is administrated in an intraperitoneal injection form, by up-regulating expression of IL-10, infiltration of neutrophil in lung tissue airways is reduced, levels of inflammatory factors and total proteins are reduced, pathological injury of lung tissues is improved, and the herbacetin has a good improvement effect on mice suffering from pneumonic injury. The invention provides a new strategy and a clinical research basis for prevention or treatment of the pneumonic injury, further provides a scientific basis for guiding clinical medication for treating the pneumonic injury, and has a relatively good application prospect.

The invention discloses a plant lactobacillus KSFY202409 and application thereof in colorectal cancer, and relates to the technical field of microorganisms. The invention discloses lactobacillus plantarum, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.31103. The lactobacillus plantarum has the advantages that the lactobacillus plantarum is prepared from lactobacillus plantarum; the invention also provides application of the plant lactobacillus in preparation of products for preventing or treating colorectal cancer, and the plant lactobacillus can effectively reduce the incidence of tumors, improve pathological injury of rectal tissues, reduce the level of inflammatory factors, down-regulate the expression of anti-apoptosis factors, up-regulate the expression of pro-apoptosis factors, and improve the colorectal cancer resistance. The strain has a remarkable effect in intervention of occurrence and development of mouse inflammation-related colorectal cancer, can be used as a potential strain for prevention and adjuvant treatment of the inflammation-related colorectal cancer, and has a wide application prospect.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum TY-P22 and application thereof, and the preservation number of the lactobacillus plantarum TY-P22 is CGMCC No: 30875. The lactobacillus plantarum TY-P22 has good artificial gastric juice resistance and bovine bile salt resistance, has the functions of remarkably improving the body immunity and improving body intestinal injury, and particularly has a relatively strong improvement effect on body immunity reduction and body intestinal injury caused by cyclophosphamide.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a medicinal and edible herbal composition for treating type II diabetes, its extract, and its applications. The medicinal and edible herbal composition of this invention includes: Astragalus membranaceus, Dioscorea opposita, Pueraria lobata, Polygonatum odoratum, Morus alba leaf, Cassia tora seed, Crataegus pinnatifida, Cinnamomum cassia, and Glycyrrhiza uralensis. The extract of this invention is an aqueous extract of the medicinal and edible herbal composition. This invention proposes a traditional Chinese medicine composition for treating type II diabetes from the perspective of medicinal and edible homology, with significant efficacy. Animal experiments have confirmed that it can treat and regulate type II diabetes from the perspectives of controlling blood sugar, regulating blood lipids, improving liver pathological damage, and improving lipid metabolism and bile acid metabolism.

This invention belongs to the field of biomedical technology, specifically relating to the application of dexphosserine in the preparation of drugs for the prevention and / or treatment of kidney injury. The dexphosserine can alleviate glycerol-induced acute kidney injury in mouse models, significantly reduce serum creatinine and urea nitrogen levels in mice with acute kidney injury, and improve kidney pathological damage, thus having a therapeutic effect on acute kidney injury and broad application prospects.

The invention discloses an application of a human milk-derived polypeptide in preparing a bronchopulmonary dysplasia prevention and treatment drug, a health product and a food additive, belongs to the field of biomedicine, and provides a new use of the human milk-derived polypeptide in preparing a bronchopulmonary dysplasia prevention and treatment drug, a health product and a food additive; the invention treats newborn mice and A549 alveolar epithelial cells with high-concentration oxygen, and simultaneously intervenes with a polypeptide MDABP derivative, detects the repair of lung tissue pathological damage, and the expression levels of alveolar type II epithelial cell marker pulmonary surfactant-associated protein C (SP-C) and alveolar type I epithelial cell marker aquaporin 5 (AQP5), and finds that the polypeptide MDABP derivative can improve alveolar epithelial cell damage caused by hyperoxia exposure, reduce apoptosis, and improve BPD lung tissue pathological damage, indicating that the polypeptide MDABP derivative intervention has an improving effect on bronchopulmonary dysplasia.

The invention discloses an active peptide capable of directionally inducing IPSCS cracking, a preparation method of the active peptide and application of the active peptide in a preparation for repairing liver injury. Experiments prove that the active peptide provided by the invention has a remarkable protective effect on a liver injury model induced by cyclophosphamide and shows a definite anti-oxidative stress effect. The result shows that a key path of chemotherapy injury can be intervened from the source by simulating or enhancing an endogenous protection mechanism of the liver. Compared with the existing exogenous synthetic drugs or single-component natural products, the product provided by the invention has the potential advantages of more comprehensive action mechanism and better biogenic property. Meanwhile, the extract is derived from directionally differentiated functional cells, and a brand new thought and material basis are provided for developing a novel chemotherapy liver protective agent which does not affect the chemotherapy curative effect and has good biocompatibility.